The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04802733
Recruitment Status : Unknown
Verified May 2022 by BlueRock Therapeutics.
Recruitment status was:  Active, not recruiting
First Posted : March 17, 2021
Last Update Posted : June 2, 2022
Memorial Sloan Kettering Cancer Center
Information provided by (Responsible Party):
BlueRock Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2024